Fortuitous synthesis of unsaturated half-sandwich Ruthenium(II) complexes via solvent-involved rearrangement and their biological evaluation
Source abstract
Abstract
Abstract A series of unsaturated (16-electron) five-coordinated ruthenium (II) complexes of the type [(η6-arene)Ru(N^N)]+PF6−, where N^N is aminoimine and η6-arene is benzene (bz) (Ru1), 3-phenylpropan-1-ol (bz-PA) (Ru2), or 4-phenylbutan-1-ol (bz-BA) (Ru3), respectively, have been serendipitously synthesized via solvent (methanol)-involved rearrangement. The identity and purity of these new complexes were determined by NMR spectroscopy, elemental analysis, mass spectrometry, and X-ray crystallography techniques. Their fluorescence property and electrochemical behavior were also investigated. These complexes showed sufficient stability and exhibited higher anticancer activity toward A549 human lung cancer cells, human cervical carcinoma cells (HeLa) and hepatocellular carcinoma cell (HepG2) than cisplatin. The investigation of structure-activity relationship displayed that Ru1 with the hydrophobic groups exhibited enhanced anticancer activity in comparison to Ru2 and Ru3 containing hydroxyl groups. Notably, complex Ru1 entered A549 human lung cancer cells through a non-energy-dependent pathway and mainly accumulated in lysosomes. Moreover, Ru1 induced a dose-dependent apoptosis and sub-G1 fraction perturbation.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Metal complexes synthesis and properties · Ferrocene Chemistry and Applications · Click Chemistry and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (53)
Show source-provided references
1. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode10.1038/205698a0 ↗
2. Cisplatin and platinum drugs at the molecular level. (Review)
3. Mirabelli, Molecular mechanisms of action of auranofin and other gold complexes as related to their biologic activities10.1016/0002-9343(83)90482-5 ↗
4. Enzyme inhibition by metal complexes: concepts, strategies and applications10.1039/c3sc22349c ↗
5. Organometallic half-sandwich iridium anticancer complexes10.1021/jm2000932 ↗
6. Organometallic–peptide bioconjugates: synthetic strategies and medicinal applications10.1021/acs.chemrev.6b00166 ↗
7. The potential of organometallic complexes in medicinal chemistry10.1016/j.cbpa.2012.01.013 ↗
8. Novel and versatile imine-N-heterocyclic carbene half-sandwich iridium(III) complexes as lysosome-targeted anticancer agents10.1021/acs.inorgchem.8b01656 ↗
9. Metallodrugs in medicinal inorganic chemistry10.1021/cr400460s ↗
10. Structure-activity relationships for highly potent half-sandwich organoiridium(III) anticancer complexes with C^N-chelated ligands10.1016/j.jinorgbio.2018.11.007 ↗
11. Exploration of the medical periodic table: towards new targets10.1039/c3cc41143e ↗
12. Lysosome-Targeted phosphine-imine half-sandwich iridium(III) anticancer complexes: synthesis, characterization, and biological activity10.1021/acs.organomet.9b00080 ↗
13. New trends in platinum and palladium complexes as antineoplastic agents10.1016/j.ccr.2015.11.004 ↗
14. Potent half-sandwich iridium(III) and ruthenium(II) anticancer complexes containing a P^O-chelated ligand10.1021/acs.organomet.8b00402 ↗
15. Design of prospective antiparasitic metal-based compounds including selected organometallic cores10.1016/j.ica.2017.07.068 ↗
16. Synthesis, characterization, antimicrobial and cytotoxic activity of novel half-sandwich Ru(II) arene complexes with benzoylthiourea derivatives10.1016/j.jinorgbio.2020.111164 ↗
17. The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials10.1039/C7CS00195A ↗
18. Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates10.1016/j.jinorgbio.2011.09.030 ↗
19. Zwitterionic and cationic half-sandwich iridium(iii) ruthenium(ii) complexes bearing sulfonate groups: synthesis, characterization and their different biological activities10.1039/C9DT00259F ↗
20. Fluorescent half-sandwich phosphine-sulfonate iridium(III) and ruthenium(II) complexes as potential lysosome-targeted anticancer agents10.1016/j.dyepig.2018.11.009 ↗
21. A lysosome-targeted ruthenium(II) polypyridyl complex as photodynamic anticancer agent10.1016/j.jinorgbio.2020.111132 ↗
22. Imine-N-Heterocyclic carbenes as versatile ligands in ruthenium(II) p-cymene anticancer complexes: a structure–activity relationship study10.1002/asia.201801058 ↗
23. Aminophosphine ligands as a privileged platform for development of antitumoral ruthenium(ii) arene complexes10.1039/C7DT03369A ↗
24. Anticancer activity of bifunctional organometallic Ru(II) arene complexes containing a 7-hydroxycoumarin group10.1021/acs.organomet.7b00842 ↗
25. Luminescent anticancer Ru(II)-arenebipyridine and phenanthroline complexes: synthesis, characterization, DFT studies, biological interactions and cellular imaging application10.1016/j.jinorgbio.2020.111099 ↗
26. Competition between glutathione and guanine for a ruthenium(II) arene anticancer complex: detection of a sulfenato intermediate10.1021/ja053387k ↗
27. Organometallic ruthenium(II) diamine anticancer Complexes: arene-nucleobase stacking and stereospecific hydrogen-bonding in guanine adducts10.1021/ja017482e ↗
28. Transfer hydrogenation catalysis in cells as a new approach to anticancer drug design10.1038/ncomms7582 ↗
29. Half-sandwich ruthenium(ii) complexes containing N^N-chelated imino-pyridyl ligands that are selectively toxic to cancer cells10.1039/C7CC08270C ↗
30. Mitochondria-targeted half-sandwich rutheniumII diimine complexes: anticancer and antimetastasis via ROS-mediated signalling10.1039/C8QI00476E ↗
31. Isolable yet highly reactive cationic organoruthenium(II) amidinates, [Ru(η6-C6R6)(η-amidinate)]+X−, showing signs of coordinative unsaturation: isoelectronic complexes of Ru(η5-C5Me5)(η-amidinate)10.1246/cl.2001.954 ↗
32. Chemistry of coordinatively unsaturated organoruthenium amidinates as entry to homogeneous catalysis10.1016/S0010-8545(03)00124-3 ↗
33. Functionalized cationic (η6-arene)ruthenium(II) complexes for site-specific and covalent anchoring to papain from papaya latex. Synthesis, X-ray structures and reactivity studies10.1016/j.tetlet.2008.05.043 ↗
34. Strategy to tether organometallic Ruthenium−Arene anticancer compounds to recombinant human serum albumin10.1021/ic701474m ↗
35. Tuning the hydrophobicity of ruthenium(ii)–arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy10.1039/b705449a ↗
36. η6-Arene complexes of ruthenium and osmium with pendant donor functionalities10.1016/j.jorganchem.2010.08.008 ↗
37. Nickel α-Keto-β-Diimine initiators for olefin polymerization10.1002/anie.200804661 ↗
38. Benzene complexes of ruthenium(II)10.1139/v72-486 ↗
39. Lysosome-targeted cyclometalated iridium (III) anticancer complexes bearing phosphine-sulfonate ligands10.1002/aoc.4746 ↗
40. Iridium(iii) complexes as therapeutic and bioimaging reagents for cellular applications10.1039/c2ra20967e ↗
41. Light-up mitophagy in live cells with dual-functional theranostic phosphorescent iridium(III) complexes10.1021/acsami.7b01735 ↗
42. Fluorescent zwitterionic Iridium(III) complexes containing sulfonate groups: synthesis, biological activity and tracking in live cells10.1016/j.dyepig.2020.108220 ↗
43. RuII(p-cymene) compounds as effective and selective anticancer candidates with No toxicity in vivo10.1021/acs.inorgchem.8b01270 ↗
44. Stimuli-responsive therapeutic metallodrugs10.1021/acs.chemrev.8b00209 ↗
45. Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function10.1038/nrm2745 ↗
46. Novel lysosome-targeted cyclometalated Iridium(III) anticancer complexes containing imine-N-heterocyclic carbene ligands: synthesis, spectroscopic properties and biological activity10.1016/j.dyepig.2018.09.044 ↗
47. Heterodinuclear Pt(iv)–Ru(ii) anticancer prodrugs to combat both drug resistance and tumor metastasis10.1039/C6CC04354B ↗
48. Lysosomal membrane permeabilization in cell death10.1038/onc.2008.310 ↗
49. Electronic effects on reactivity and anticancer activity by half-sandwich N,N-chelated iridium(iii) complexes10.1039/C8NJ03360A ↗
50. Metal-based anticancer chemotherapeutic agents10.1016/j.cbpa.2014.02.003 ↗
51. Flow cytometry of caspase-3 activation in preapoptotic leukemic cells10.1002/(SICI)1097-0320(20000601)40:2<151::AID-CYTO9>3.0.CO;2-9 ↗
52. A dual-targeting, apoptosis-inducing organometallic half-sandwich iridium anticancer complex10.1039/C4MT00112E ↗
53. Significant effects of counteranions on the anticancer activity of iridium(iii) complexes10.1039/C8CC01326H ↗